Soret, Perrine
Vandenborght, Louise-Eva
Francis, Florence
Coron, Noémie
Enaud, Raphael
Avalos, Marta
Schaeverbeke, Thierry
Berger, Patrick
Fayon, Michael
Thiebaut, Rodolphe
Delhaes, Laurence
Chabe, Magali
Audebert, Christophe
Durand-Joly, Isabelle
Boldron, Amale
Pin, Isabelle
Cognet, Odile
Pelloux, Herve
Prevotat, Anne
Wallaert, Benoit
Wizla, Nathalie
Thumerelle, Caroline
Turck, Dominique
,
Funding for this research was provided by:
Genoscreen company
Association Vaincre la Mucoviscidose (RF20160501626)
Article History
Received: 8 January 2019
Accepted: 14 October 2019
First Online: 27 February 2020
Competing interests
: Pr L. Delhaes is member of the scientific advisory board of “Vaincre la Mucoviscidose”, and of the executive committee of ESGHAMI (ESCMID working group). She also did punctual consulting for pharmaceutical companies (Pfizer, Gilead, and MSD) and was invited to participate to scientific congresses as compensations. The other authors declare no potential conflict of interest.